EC21

EC21: sourced facts only. name: "Here, we report the design and synthesis of a bifunctional small molecule, EC21, capable of simultaneously engaging CDK6 and EYA2." [PMID:42335715]; target: "Here, we report the design and synthesis of a bifunctional small molecule, EC21, capable of simultaneously engaging CDK6 and EYA2." [PMID:42335715]; target: "Here, we report the design and synthesis of a bifunctional small molecule, EC21, capable of simultaneously engaging CDK6 and EYA2." [PMID:42335715]; developer: "School of Pharmacy, Anhui Medical University, Hefei, Anhui, 230032, China." [PMID:42335715]; modality: "Here, we report the design and synthesis of a bifunctional small molecule, EC21, capable of simultaneously engaging CDK6 and EYA2." [PMID:42335715]; stage: "Importantly, EC21 exhibited pronounced antitumor activity in a syngeneic breast cancer mouse model and reduced EYA2 protein levels in tumor tissues without apparent toxicity." [PMID:42335715]